Amgen Inc.

AMGN remains in a constructive multi-month uptrend, trading above both its 50-day and 200-day moving averages. The stock is still near the top of its 52-week range, which keeps the longer-term regime bullish even after a modest pullback from the highs.

Street sentiment is positive but not euphoric: the consensus rating sits at Buy, while the average target of about $364.71 is below the last close, implying limited upside from here. Recent action has been mostly target resets and reiterations, including UBS to $420 and Barclays to $360, with no broad rating deterioration.

The setup favors another solid report after seven straight EPS beats, including 8.0% and 11.8% surprises in the last two quarters. Analysts expect EPS to rise to 23.44 next year from 14.38 TTM, so shareholders should watch for guidance that supports that step-up.

No notable discretionary insider buying or selling. Recent filings are dominated by automatic award and in-kind transactions for directors and officers, which read as compensation-related noise rather than a directional signal.

Profitability is strong, with a 71.4% gross margin, 33.8% operating margin, and 21.0% net margin. Growth is steady rather than explosive, with revenue up 5.8% year over year and earnings up 4.4%, while free cash flow reached $11.82 billion in 2025.

AMGN screens as a high-quality large-cap biotech with better margins and cash generation than many peers, but it also carries a heavy debt load of $54.6 billion. At 17.43x earnings, the valuation is reasonable for the sector, though not a deep discount.